Advertisement

Journal of Endocrinological Investigation

, Volume 29, Issue 3, pp 261–264 | Cite as

The IGF system in a case of Costello syndrome

  • A. Barreca
  • M. Cotellessa
  • M. Boschetti
  • A. Giannattasio
  • L. Cresta
  • C. Schiaffino
  • R. Lorini
Case Report

Abstract

Costello syndrome is characterized by facial dysmorphia, hyperpigmented skin, palmar and plantar hyperkeratosis, curly hair, perioral and nasal papillomata (more rarely localized anally and on vocal cords), short stature, mental retardation and sociable personality. Although growth retardation is typical of Costello syndrome, its cause is not defined. We report on a 10-yr-old Caucasian girl affected by Costello syndrome with fasting hypoglycemia and short stature, associated low circulating levels of acid-labile subunit (ALS), relatively low levels of IGF-I and IGFBP-3, and normal IGF-II, mostly circulating in a binary complex with IGFBP-2 and -6 instead of in a 150 kDa ternary complex. The reduced ALS concentration and the consequent impaired formation of the circulating 150 kDa ternary complex can induce an accelerated clearance rate of IGF peptides and of IGFBP-3, contributing to the decreased IGF-I growth promoting activity in our patient. Moreover, the presence of IGF-II in the binary complex, which has been postulated to increase the insulin-like effects of these peptides, can explain, at least in part, the patient’s asymptomatic fasting hypoglycemia. (J. Endocrinol. Invest. 29: 261–264, 2006)

Key Words

Costello syndrome growth delay hypoglycemia GH IGFs IGFBPs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Costello JM. A new syndrome: Mental subnormality and nasal papillomata. Aust Paediatr J 1977, 13: 114–8.PubMedGoogle Scholar
  2. 2.
    Der Kalousian V.M., Moroz B., McIntosh N., Watters K., Blaichman S. Costello syndrome. Am J Med Genet 1991, 4: 69–73.Google Scholar
  3. 3.
    Zampino G, Mostroiacovo P, Ricci R, et al. Costello syndrome: further clinical delineation, natural history, genetic definition, and nosology. Am J Med Genet 1993, 47: 176–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Borochowitz Z, Pavone L, Mazor G, Rizzo R, Dar H. New multiple congenital anomalies: mental retardation syndrome (MCA/MR) with facio-cutaneous-skeletal involvement. Am J Med Genet 1992, 43: 678–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Lurie IW. Genetics of the Costello syndrome. Am J Med Genet 1994, 52: 358–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Johnson JP, Golabi M, Norton ME, et al. Costello syndrome: Phenotype, natural history, differential diagnosis, and possible cause. J Pediatr 1998, 133: 441–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Okamoto N, Chiyo H, Imai K, Otani K, Futagi Y. A Japanese patient with the Costello syndrome. Hum Genet 1994, 93: 605–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Legault L, Gagnon C, Lapointe N. Growth hormone deficiency in Costello syndrome: A possible explanation for the short stature. J Pediatr 2001, 138: 151–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Di Rocco M, Gatti R, Gandullia P, Barabino A, Picco P, Borrone C. Report on two patients with Costello syndrome and sialuria. Am J Med Genet 1993, 47: 1135–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem 1989, 264: 11843–8.PubMedGoogle Scholar
  11. 11.
    Barreca A, Ponzani P, Arvigo M, Giordano G, Minuto F. Effect of the acid-labile subunit on the binding of insulin-like growth factor (IGF)-binding protein-3 to [125I]IGF-I. J Clin Endocrinol Metab 1995, 80: 1318–24.PubMedGoogle Scholar
  12. 12.
    Zapf J, Schmid C, Froesch ER. Biological and immunological properties of insulin-like growth factors I and II. J Clin Endocrinol Metab 1984, 13: 3–30.CrossRefGoogle Scholar
  13. 13.
    Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. Diagnostic value of the acid-labile subunit (ALS) in acromegaly. Evaluation in comparison with insulin-like growth factor (IGF)-I, and IGF binding proteins (IGFBP-1, -2, -and -3). J Clin Endocrinol Metab 2001, 86: 1091–8.PubMedGoogle Scholar
  14. 14.
    Jones J, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16: 3–34.PubMedGoogle Scholar
  15. 15.
    Zapf J, Hauri C, Futo E, et al. Intravenously injected insulin-like growth factor (IGF) I/GF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 1995, 95: 179–86.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Endocrinology 1996, 137: 1913–20.PubMedGoogle Scholar
  17. 17.
    Murphy LJ, Molnar P, Lu X, Huang H Expression of human insulin-like growth factor binding protein-3 in transgenic mice]. J Mol Endocrinol 1995, 15: 293–303PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2006

Authors and Affiliations

  • A. Barreca
    • 1
  • M. Cotellessa
    • 2
  • M. Boschetti
    • 1
  • A. Giannattasio
    • 2
  • L. Cresta
    • 2
  • C. Schiaffino
    • 2
  • R. Lorini
    • 2
  1. 1.Department of Endocrinology and MetabolismUniversity of GenovaGenovaItaly
  2. 2.Department of Paediatrics, G. Gaslini Scientific InstituteUniversity of GenoaGenoaItaly

Personalised recommendations